期刊文献+

生物可降解性紫杉醇支架预防血管再狭窄的实验研究 被引量:3

The study of drug eluting biodegradable intravascular stent with antiproliferation agent-paclitaxel in preventing vascular restenosis
原文传递
导出
摘要 目的 探讨生物可降解性紫杉醇支架防治血管再狭窄的作用。方法 制备“Z形”聚左旋乳酸 (PLLA)裸支架和含抗增生药物紫杉醇 6 0 μg的PLLA支架。应用 7F球囊对 8只犬肾动脉以下的腹主动脉进行 2处扩张 ,制成血管再狭窄模型。按照解剖标志分别将裸支架和紫杉醇支架置入扩张后的腹主动脉处。支架置入术后 6周处死实验犬取出标本行组织病理、形态学测量和免疫组织化学分析。结果 裸支架组血管平均管腔面积为 (775 86 5± 6 6 0 ) μm2 ;紫杉醇支架组血管平均管腔面积为 (113435 9± 71 0 ) μm2 ,紫杉醇支架组管腔平均面积大于裸支架组 (P <0 0 1)。裸支架组血管新生内膜平均增生面积为 :(2 4 80 3± 5 6 ) μm2 ;紫杉醇组平均内膜增生面积为 (12 931± 6 3) μm2 ,紫杉醇支架组新生内膜平均面积明显小于裸支架组 (P <0 0 1)。裸支架组增殖细胞核抗原 (PCNA)细胞阳性率为 (38± 15 ) % ;紫杉醇支架组为 (11± 0 31) % ,两组差异有显著性意义 (P <0 0 1)。结论 生物可降解性血管内支架作为载荷和释放药物的有效平台 ,通过携带抗增生药物紫杉醇可以显著抑制血管平滑肌细胞的增殖和血管内膜的增生 ,是防治血管再狭窄的理想手段。 Objective To define the effect of drug eluting BIS with antiproliferation agent-paclitaxel in preventing vascular restenosis.Methods Bare BIS and drug BIS with 60 μg paclitaxel were prepared. Both types of the BIS were implanted into the infrarenal restenosis aortas in canine models, and the animals were euthanized 6 weeks after implantation for histopathological, morphometric and immunohistochemical assessment.Results The mean lumen area of bare BIS group was (77 586.5±66.0) μm2, and lumen of paclitaxel eluting BIS group was (113 435.9±71.0) μm2. The mean neointima area of bare BIS group was (24 803±56) μm2, and paclitaxel eluting BIS group was (12 931±63) μm2. The PCNA-positive ratio was (38±15)% in bare BIS group and (11±0.31)% in paclitaxel eluting BIS group. The statistically significant difference between the two groups were noted ( P <0.01). Conclusion BIS as a vehicle of loading and releasing drugs could significantly inhibit the VSMC and neointimal hyperplasia with antiproliferation agent-paclitaxel. BIS is a promising and new strategy in preventing the restenosis.
出处 《中华放射学杂志》 CAS CSCD 北大核心 2004年第5期534-538,共5页 Chinese Journal of Radiology
基金 国家自然科学基金资助项目 ( 3 0 2 70 416) 国家发明专利 (申请号 :0 2 10 40 71.0 )
关键词 生物可降解性紫杉醇支架 预防 血管再狭窄 实验研究 Stent Biodegradation Graft occlusion, vascular Chemoprevention
  • 引文网络
  • 相关文献

参考文献17

  • 1Gruntzig AR,Senning A,Siegenthaler WE.Nonoperative dilatation of coronary artery stenosis:percutaneous transluminal coronary angioplasty.N Eng J Med,1979,301:61-68.
  • 2Popma JJ,Califf RM,Topol EJ.Clinical trials of restenosis after coronary angioplasty.Circulation,1991,84:1426-1436.
  • 3Herdeg C,Oberhoff M,Karsch KR.Antiproliferative stent coatings:taxol and related compounds (Review).Semin Interv Cardiol,1998,3:197-199.
  • 4Liu MW,Roubin GS,King SB.Restenosis after coronary angioplasty:potential biologic determinants and role of intimal hyperplasia (Review).Circulation,1989,79:1374-1387.
  • 5Clowes AW,Cloews MM,Au YP,et al.Smooth muscle cells express urokinase during mitogenesis and tissue-type plasminogen activator during migration in injured rat carotid artery.Circ Res,1990,67:61-67.
  • 6Farb A,Heller PF,Shroff S,et al.Pathological analysis of local delivery of paclitaxel via a polymer-coated stent.Circulation,2001,104:473-479.
  • 7Sollott SJ,Cheng L,Pauly RR,et al.Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat.J Clin Invest,1995,95:1869-1876.
  • 8Axel DI,Kunert W,Goggelmann C,et al.Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery.Circulation,1997,96:636-645.
  • 9Kipshidze N,Moses JW,Leon MB.Paclitaxel-coated stent:is there a light at the end of the tunnel? J Am Coll Cardiol,2001,38:292-293.
  • 10Baumbach A,Herdeg C,Kluge M,et al.Local drug delivery:impact of pressure,substance characteristics,and stenting on drug transfer into the arterial wall.Catheter Cardiovasc Interv,1999,47:102-106.

二级参考文献34

  • 1张金山.严格掌握金属内支架置入术的适应证[J].中华放射学杂志,1998,32(10):653-654.
  • 2Lincoff AM, Furst JG, Ellis SG, et al. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol, 1997, 29:808-816.
  • 3Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation, 2000, 102:399-404.
  • 4Vasenius J, Vainionpaa S, Vihtonen K, et al. Comparison of in vitro hydrolysis, subcutaneous and intramedullary implantation to evaluate the strength retention of absorbable osteosynthesis implants. Biomaterials, 1990, 11: 501- 504.
  • 5欧阳墉. 管腔内支架的作用机制和性能. 见:张金山,主编.现代腹部介入放射学. 北京:科学出版社,2000.239-241.
  • 6Stack TE, Califf RM, Phillips HR, et al. Interventional cardiac catheterization at Duke medical center. Am J Cardiol, 1988, 62(Suppl F): 3-24.
  • 7Fichman DL, Leon MB, Baim DS. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl Med, 1994, 331:496-501.
  • 8Carrozza JP Jr, Kuntz RE, Levine MJ, et al. Angiographic and clinical outcome of intracoronary stenting: immediate and long-term results from a large single-center experience. J Am Coll Cardiol, 1992,20:328-337.
  • 9Rajasubramanian G, Meidell RS, Landau C, et al. Fabrication of resorbable microporous intravascular stents for gene therapy applications. ASAIO J, 1994, 40:M584-589.
  • 10Ye YW, Landau C, Meidell RS, et al. Improved bioresorbable microporous intravascular stents for gene therapy. ASAIO J, 1996, 42: M823-827.

共引文献37

同被引文献129

引证文献3

二级引证文献10

;
使用帮助 返回顶部